Altratech has discovered and patented a fundamentally novel process to detect and quantify DNA, RNA, Antibody, and Antigen molecular targets. Our key breakthrough is that our process replaces the need for time consuming ‘biological amplification’ required for optical read-outs, with almost instant ‘electronic signal amplification’ and a digital read-out. This will enable market-disrupting products that have the simplicity of a pregnancy test and the performance of a laboratory PCR test.

We are a team of twenty scientists engineers, including nine PhDs, has for the past seven years been researching and developing a Bioorthogonal alternative to PCR. With minimal sample preparation, the Altratech product and assay can rapidly detect and quantify molecular targets from any sample. The technology brings together nanotechnology, CMOS semiconductor technology and novel PNA chemistry to produce a unique and powerful assay. The assay named Molecular Detection by Proxy is a bead-based technology coupled with ultra-sensitive capacitance detection.

We are creating an infrastructure of technology and data to manage contagious viral diseases, important for the future of decentralised connected healthcare and wellbeing.

Based on the novel Detection by Proxy concept, Altratech has developed the next generation of molecular detection. The technology enables any person, anywhere, to rapidly and accurately measure and quantify viral RNA, DNA, antigen, or antibody samples.